Large Unmet Treatment Need – Vaccine Coverage Largely Falls Short
Only about a third of U.S. adults have the highest level of available protection against the coronavirus, saying they have been fully vaccinated and have received a booster shot within the last six months.
— PEW Research Center Study (May, 2023)
Influenza Vaccination Coverage
For all people ≥6 months during 2021-22 season (U.S.)
COVID-19 Fully Vaccinated
Number of U.S. adults receiving updated booster (U.S.)
Sources: cdc.gov, NY Times
Inhalon’s Test-to-Treatment Model
Inhalon is developing inhaled antibody treatments that are designed to provide immediate intervention, be self-administered, and work for all age groups.
Patients are treated by inhaling an antibody mist that is generated by a handheld nebulizer. Inhalon uses vibrating nebulizers from third-parties to aerosolize the antibody drug without changing the antibody's properties.
Inhalon's muco-trapping antibodies are designed to come in single-use containers that can easily be poured into the nebulizer. Patients inhale the antibody drug for 3 to 5 minutes using the nebulizer mouthpiece or mask. This process is repeated for 3 to 5 days depending on the indication.